Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima Prefecture, Japan.
J Pediatr Hematol Oncol. 2022 Mar 1;44(2):62-64. doi: 10.1097/MPH.0000000000002079.
Herein, we describe a 14-year-old female patient with B-cell precursor acute lymphoblastic leukemia who relapsed in early consolidation. Minimal residual disease-negative complete remission was obtained after 1 cycle of inotuzumab ozogamicin therapy. She underwent HLA-haploidentical peripheral blood stem cell transplantation after a myeloablative conditioning regimen. Posttransplant cyclophosphamide, tacrolimus, and mycophenolate mofetil were administered for the prophylaxis of graft-versus-host disease. At 23 months, she was in complete remission. Although the administration of inotuzumab ozogamicin followed by haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide has been limited in children, this strategy may be an effective treatment for pediatric refractory acute lymphoblastic leukemia.
在此，我们描述了一位 14 岁的女性 B 细胞前体急性淋巴细胞白血病患者，她在早期巩固治疗中复发。经过 1 个周期的奥加曲妥珠单抗治疗后，获得了微小残留病阴性完全缓解。在接受清髓性预处理方案后，她接受了 HLA 单倍体外周血造血干细胞移植。移植后环磷酰胺、他克莫司和霉酚酸酯用于预防移植物抗宿主病。23 个月时，她处于完全缓解状态。尽管在儿童中，奥加曲妥珠单抗治疗后进行单倍体外周血造血干细胞移植并联合移植后环磷酰胺的应用受到限制，但这种策略可能是治疗儿童难治性急性淋巴细胞白血病的有效方法。
